共 50 条
- [31] Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)BLOOD, 2019, 134Lampson, Benjamin L.Tyekucheva, SvitlanaCrombie, Jennifer L.Kim, Austin I.Merryman, Reid W.Lowney, JessicaMontegaard, JosiePatterson, VictoriaJacobson, Caron A.Jacobsen, Eric D.LaCasce, Ann S.Arnason, Jon E.Armand, PhilippeFisher, David C.Brown, Jennifer R.Davids, Matthew S.
- [32] Majic: A Phase 3 Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaBLOOD, 2021, 138Davids, Matthew S.Mato, Anthony R.Hum, JulietteWargo, SusanaEmeribe, UgochinyereShahkarami, MinaSokolowski, KevinBiondo, Juliana M. L.Abhyankar, SarangHermann, RickSharman, Jeff P.
- [33] Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphomaBLOOD ADVANCES, 2020, 4 (19) : 4802 - 4811Tam, Constantine S.Quach, HangNicol, AndrewBadoux, XavierRose, HannahPrince, H. MilesLeahy, Michael F.Eek, RichardWickham, NicholasPatil, Sushrut S.Huang, JanePrathikanti, RadhaCohen, AileenElstrom, RebeccaReed, WilliamSchneider, JingjingFlinn, Ian W.
- [34] ACALABRUTINIB (AKA) VERSUS VENETOCLAX WITH OBINUTUZUMAB (VEN plus OBI) IN PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND UNMUTATED IGHV GENES - INDIRECT COMPARISONVALUE IN HEALTH, 2023, 26 (12) : S39 - S39Kaczynski, L.Kowal, P.Wojcik, R.Kaczor, M. P.
- [35] Safety and Efficacy of Obinutuzumab Plus Fludarabine and Cyclophosphamide in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the GREEN StudyBLOOD, 2017, 130Leblond, VeroniqueCantin, GuyCortelezzi, AgostinoKnauf, WolfgangTiab, MouradTurgut, MehmetZaritskey, AndreyMerot, Jean-LouisTrunzer, KerstinRobson, SusanGresko, EkaterinaStilgenbauer, StephanFoa, RobinBosch, Francesc
- [36] Matching-Adjusted Indirect Treatment Comparison (MAIC) of Acalabrutinib Alone or in Combination with Obinutuzumab Versus Ibrutinib or Venetoclax Plus Obinutuzumab in Patients with Treatment-Naive Chronic Lymphocytic LeukemiaBLOOD, 2021, 138Davids, Matthew S.Emeribe, UgochinyereGaitonde, PriyankaCai, Ling
- [37] The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic LeukemiaBLOOD, 2023, 142Al-Sawaf, OthmanFuerstenau, MoritzGiza, AdamRobrecht, SandraVon Tresckow, JuliaFink, Anna MariaSimon, FlorianTausch, EugenSchneider, ChristofSivcheva, LiliyaSchwarer, AnthonyLoscertales, JavierWeinkove, RobertStrumberg, DirkKilfoyle, Allanah R.Juliusson, GunnarDa Cunha-Bang, CasparIllmer, ThomasGregor, MichaelThornton, PatrickJanssens, AnnTadmor, TamarLindstrom, VesaStaber, Philipp BernhardLevin, Mark-DavidWendtner, Clemens-MartinKreuzer, Karl-AntonRitgen, MatthiasStilgenbauer, StephanKater, Arnon P.Niemann, Carsten UtoftFischer, KirstenEichhorst, Barbara F.Hallek, Michael
- [39] Cost-Utility of Venetoclax Plus Obinutuzumab for Treatment-Naive Patients with Chronic Lymphocytic Leukemia without Del17p/TP53-Mutation Compared to Chlorambucil Plus ObinutuzumabBLOOD, 2022, 140 : 2163 - 2164Slot, MatildeNiemann, Carsten UtoftRisor, Bettina WulffEhlers, Lars HolgerRotbain, Emelie
- [40] Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemiaBLOOD, 2022, 139 (09) : 1318 - 1329Huber, HenrietteEdenhofer, Simonevon Tresckow, JuliaRobrecht, SandraZhang, CanTausch, EugenSchneider, ChristofBloehdorn, JohannesFuerstenau, MoritzDreger, PeterRitgen, MatthiasIllmer, ThomasIllert, Anna L.Duerig, JanBoettcher, SebastianNiemann, Carsten U.Kneba, MichaelFink, Anna-MariaFischer, KirstenDoehner, HartmutHallek, MichaelEichhorst, BarbaraStilgenbauer, Stephan